Great Lakes Advisors LLC decreased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 34.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 195,290 shares of the biopharmaceutical company’s stock after selling 104,611 shares during the quarter. Great Lakes Advisors LLC’s holdings in Revance Therapeutics were worth $4,943,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. WASHINGTON TRUST Co acquired a new stake in Revance Therapeutics during the 1st quarter valued at approximately $36,000. Signaturefd LLC lifted its position in Revance Therapeutics by 792.9% during the first quarter. Signaturefd LLC now owns 1,393 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,237 shares during the period. Baldwin Brothers LLC MA lifted its position in Revance Therapeutics by 300.0% during the second quarter. Baldwin Brothers LLC MA now owns 2,000 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 1,500 shares during the period. Money Concepts Capital Corp purchased a new stake in Revance Therapeutics in the fourth quarter valued at $40,000. Finally, Advisor Group Holdings Inc. grew its position in Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,071 shares during the period. Institutional investors and hedge funds own 93.28% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently commented on RVNC shares. BNP Paribas raised Revance Therapeutics from an “underperform” rating to a “neutral” rating and set a $20.00 target price on the stock in a report on Wednesday, August 16th. HC Wainwright dropped their price objective on shares of Revance Therapeutics from $41.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, November 6th. Morgan Stanley decreased their target price on shares of Revance Therapeutics from $25.00 to $12.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 11th. StockNews.com started coverage on shares of Revance Therapeutics in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Finally, Barclays decreased their price objective on shares of Revance Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Monday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.44.
Revance Therapeutics Stock Up 2.7 %
Shares of NASDAQ RVNC opened at $7.47 on Tuesday. The firm has a market cap of $655.50 million, a price-to-earnings ratio of -1.50 and a beta of 0.92. The company’s 50-day simple moving average is $10.09 and its 200-day simple moving average is $19.84. The company has a quick ratio of 4.17, a current ratio of 4.73 and a debt-to-equity ratio of 14.20. Revance Therapeutics, Inc. has a 52-week low of $5.72 and a 52-week high of $37.98.
Insider Activity at Revance Therapeutics
In other Revance Therapeutics news, SVP Dwight Moxie sold 23,853 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $17.81, for a total transaction of $424,821.93. Following the completion of the transaction, the senior vice president now owns 55,066 shares of the company’s stock, valued at $980,725.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.
Revance Therapeutics Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
- Five stocks we like better than Revance Therapeutics
- How to Use Stock Screeners to Find Stocks
- Safeguard your portfolio with these three bargain stocks
- Are Penny Stocks a Good Fit for Your Portfolio?
- Membership clubs gain leverage for the consumer rebound
- Investing in large cap stocks: Diving into big caps
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.